Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.
Jia H, Pallos J, Jacques V, Lau A, Tang B, Cooper A, Syed A, Purcell J, Chen Y, Sharma S, Sangrey GR, Darnell SB, Plasterer H, Sadri-Vakili G, Gottesfeld JM, Thompson LM, Rusche JR, Marsh JL, Thomas EA.
Jia H, et al. Among authors: gottesfeld jm.
Neurobiol Dis. 2012 May;46(2):351-61. doi: 10.1016/j.nbd.2012.01.016.
Neurobiol Dis. 2012.
PMID: 22590724
Free PMC article.